

For Immediate Release

Respironics' Media

Contacts:

Amy Nesbitt
Blattner Brunner
Public Relations
412-995-9614

Reynee Tung
Respironics, Inc.
Manager, Marketing Comm.
760-918-7477

Respironics Releases CAPNOSTAT[®] 5 Mainstream CO₂ Sensor

Murrysville, PA, – March 30, 2005 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP) introduces the CAPNOSTAT[®] 5 Mainstream CO₂ Sensor, the next generation in CO₂ monitoring technology for use during anesthesia, recovery, in the intensive care unit (ICU), and in emergency medicine/transport or respiratory care.

Easily integrated with virtually any patient monitoring system, the CAPNOSTAT 5 Sensor provides technologically advanced measurement of End-Tidal Carbon Dioxide (ETCO₂) and respiration rate, as well as a clear, accurate capnogram at respiratory rates of up to 150 breaths per minute. Designed for mainstream sampling, the CAPNOSTAT 5 uses sophisticated infrared absorption spectroscopy to measure ETCO₂ directly at the patient's airway so response time is faster and there is less chance for erroneous data.

The CAPNOSTAT 5 Sensor incorporates a new miniature PC board that places all measurement and analysis function inside the actual sensor head. This innovation eliminates the need for an additional PC board inside the host monitor, conserving scarce architecture and reducing technology acquisition costs. This highly flexible device uses a simple RS-232 signal so data output is easily recognized and integration with other monitoring systems is simple and affordable.

According to Michael Bunnell, Vice President of Sales and Marketing, Respironics Hospital Division, "The introduction of the CAPNOSTAT 5 Sensor solidifies Respironics' position as the global leader in capnography

while taking ETCO₂ technology to a new level. It provides OEM opportunities for a complete integration solution and it will ensure respiratory monitoring capabilities that provide invaluable benefits for patients and their caregivers both now and in the future.”

The CAPNOSTAT 5 Mainstream CO₂ Sensor joins the Respironics family of other OEM technologies, such as FloTrak™ Respiratory Mechanics Module, and respiratory monitoring products such as the NICO® Cardiopulmonary Monitor and the Tidal Wave® Handheld CO₂ Capnograph, both available for private label opportunities. Respironics also provides comprehensive engineering, clinical and marketing support services to help OEM customers.

About Respironics

Respironics' Hospital Division is focused on advancing the science and practice of respiratory care. The Division offers a single source for invasive and noninvasive cardiorespiratory diagnostic and therapeutic resources. Products include ventilators, monitors, disposable masks and accessories, pulse oximeters, and capnography devices.

Respironics is a leading developer, manufacturer and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in more than 125 countries and employs 3,500 associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

#

This document contains forward-looking statements, including statements relating to, among other things, developments in the healthcare industry; the success of the Company's marketing, sales, and promotion programs; future sales and acceptance of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements and enforcement actions; future results from acquisitions; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States (including potential future effects of the change in sovereignty of Hong Kong); foreign currency fluctuations; customer consolidation and concentration; increasing price competition and other competitive factors in the sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; and third party reimbursement, all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K.